- Home
- LIMN vs NBBK Comparison
LIMN vs NBBK Comparison
Compare LIMN & NBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIMN
- NBBK
- Stock Information
- Founded
- LIMN 2018
- NBBK 1892
- Country
- LIMN United States
- NBBK United States
- Employees
- LIMN N/A
- NBBK N/A
- Industry
- LIMN
- NBBK
- Sector
- LIMN
- NBBK
- Exchange
- LIMN NYSE
- NBBK Nasdaq
- Market Cap
- LIMN 623.8M
- NBBK 687.7M
- IPO Year
- LIMN N/A
- NBBK N/A
- Fundamental
- Price
- LIMN $6.65
- NBBK $19.07
- Analyst Decision
- LIMN
- NBBK Buy
- Analyst Count
- LIMN 0
- NBBK 1
- Target Price
- LIMN N/A
- NBBK $22.00
- AVG Volume (30 Days)
- LIMN 510.5K
- NBBK 367.8K
- Earning Date
- LIMN 01-01-0001
- NBBK 07-23-2025
- Dividend Yield
- LIMN N/A
- NBBK N/A
- EPS Growth
- LIMN N/A
- NBBK 421.39
- EPS
- LIMN N/A
- NBBK 1.18
- Revenue
- LIMN N/A
- NBBK $169,131,000.00
- Revenue This Year
- LIMN N/A
- NBBK N/A
- Revenue Next Year
- LIMN N/A
- NBBK N/A
- P/E Ratio
- LIMN N/A
- NBBK $16.22
- Revenue Growth
- LIMN N/A
- NBBK 27.71
- 52 Week Low
- LIMN $4.40
- NBBK $15.09
- 52 Week High
- LIMN $33.66
- NBBK $21.05
- Technical
- Relative Strength Index (RSI)
- LIMN N/A
- NBBK 74.84
- Support Level
- LIMN N/A
- NBBK $18.14
- Resistance Level
- LIMN N/A
- NBBK $19.15
- Average True Range (ATR)
- LIMN 0.00
- NBBK 0.51
- MACD
- LIMN 0.00
- NBBK 0.18
- Stochastic Oscillator
- LIMN 0.00
- NBBK 97.42
About LIMN LIMINATUS PHARMA INC
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.